Dr. Raymond S. Lord

Hematology Oncology
200 N Park St, 
Kalamazoo, MI 
Accepting New Patients
200 N Park St, 
Kalamazoo, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Raymond Lord is a Hematologist Oncology provider in Kalamazoo, Michigan. Dr. Lord is currently accepting new patients.

His clinical research consists of co-authoring 4 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in MI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

200 N Park St, Kalamazoo, MI 49007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Intergroup Randomized Phase 2 Four Arm Study In Patients ≥ 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Enrollment Status: Active_not_recruiting
Publish Date: April 08, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustine Hydrochloride, Bortezomib, Lenalidomide
Study Phase: Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

4 Total Publications

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
Journal: Clinical breast cancer
Published: March 09, 2016
Similar Doctors
Expertise in
43
conditions
Dr. Dustin A. Bivins
Hematology Oncology | Hematology | Oncology
Expertise in
43
conditions
Dr. Dustin A. Bivins
Hematology Oncology | Hematology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (0.7 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dustin Bivins is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Bivins is highly rated in 43 conditions, according to our data. His top areas of expertise are Gliosarcoma, Embryonal Tumor with Multilayered Rosettes, Neuroepithelioma, and Atypical Teratoid Rhabdoid Tumor (ATRT). Dr. Bivins is currently accepting new patients.

Expertise in
52
conditions
Dr. Mohammad Omaira
Hematology Oncology | Hematology | Oncology
Expertise in
52
conditions
Dr. Mohammad Omaira
Hematology Oncology | Hematology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (0.7 miles away)
269-286-7170
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohammad Omaira is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Omaira is highly rated in 52 conditions, according to our data. His top areas of expertise are Monoclonal Gammopathy of Undetermined Significance (MGUS), Small Lymphocytic Lymphoma (SLL), Large-Cell Immunoblastic Lymphoma, and Chronic Lymphocytic Leukemia (CLL). Dr. Omaira is currently accepting new patients.

Expertise in
32
conditions
Dr. Sunil Nagpal
Hematology Oncology | Hematology | Oncology
Expertise in
32
conditions
Dr. Sunil Nagpal
Hematology Oncology | Hematology | Oncology

Bronson Methodist Hospital

805 John St, 
Kalamazoo, MI 
 (0.7 miles away)
269-286-7170
Languages Spoken:
English, Hindi, Punjabi
See accepted insurances
Accepting New Patients
Offers Telehealth

Sunil Nagpal is a Hematologist Oncology specialist and a Hematologist in Kalamazoo, Michigan. Dr. Nagpal is highly rated in 32 conditions, according to our data. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Tissue Biopsy. Dr. Nagpal is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lord's expertise for a condition
ConditionClose

We do not have enough information to identify the Areas of Expertise for this provider.

Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile